

# References

## Chapter 42

- 1 Institute for Healthcare Informatics. The Global Use of Medicines: Outlook Through 2017. Available from: <http://www.imshealth.com/en/thought-leadership/ims-institute/reports/global-use-of-medicines-outlook-through-2017> (last accessed 18 November 2015).
- 2 Drummond MF. *Methods for the Economic Evaluation of Health Care Programmes*. Oxford, Oxford University Press, 2005.
- 3 Byford S, Raftery J. Perspectives in economic evaluation. *British Medical Journal*. 1998;**316**:1529–30.
- 4 Hill SR, Mitchell AS, Henry DA. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. *Journal of the American Medical Association*. 2000;**283**:2116–21.
- 5 Anis AH, Rahman T, Schechter MT. Using pharmacoeconomic analysis to make drug insurance coverage decisions. *Pharmacoeconomics*. 1998;**13**:119–26.
- 6 Commonwealth Department of Health and Ageing. Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee. Canberra, Commonwealth of Australia, 1992.
- 7 Ontario Ministry of Health and Long-Term Care. Ontario Guidelines for Economic Analysis of Pharmaceutical Products. Available from: [http://www.health.gov.on.ca/en/pro/programs/drugs/economic/economic\\_mn.aspx](http://www.health.gov.on.ca/en/pro/programs/drugs/economic/economic_mn.aspx) (last accessed 18 November 2015).
- 8 Langley PC. Formulary submission guidelines for Blue Cross and Blue Shield of Colorado and Nevada. Structure, application and manufacturer responsibilities. *Pharmacoeconomics*. 1999;**16**:211–24.
- 9 Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. *Value in Health*. 2013;**16**:e1–5.
- 10 Sculpher MJ, Claxton K, Drummond M, McCabe C. Whither trial-based economic evaluation for health care decision making? *Health Economics*. 2006;**15**:677–87.
- 11 Hughes DA. Modelling in health economics. In: Walley T, Haycox A, Boland A, eds. *Pharmacoeconomics*. Edinburgh, Churchill Livingstone, 2004.
- 12 Weinstein MC. Recent developments in decision-analytic modelling for economic evaluation. *Pharmacoeconomics*. 2006;**24**:1043–53.
- 13 Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. *Health Economics*. 2006;**15**:1295–310.
- 14 Rochau U, Jahn B, Qerimi V, Burger EA, Kurtzthaler C, Klubenschaedl M, et al. Decision-analytic modeling studies: an overview for clinicians using multiple myeloma as an example. *Critical Reviews in Oncology & Hematology*. 2015;**94**(2):164–78.
- 15 Petrou S, Gray A. Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting. *British Medical Journal*. 2011;**342**:d1766.
- 16 Steele MJ. Dimensions of credibility in models and simulations. Proceedings of the 2008 Summer Computer Simulation Conference. Article No. 57. Available from: <http://dl.acm.org/citation.cfm?id=2367713> (last accessed 18 November 2015).
- 17 Lorscheid I, Heine BO, Meyer M. Opening the ‘back box’ of simulations: increased transparency of simulation models and effective results reports through the systematic design of experiments. *Computational and Mathematical Organization Theory*. 2012;**18**(1):22–62.
- 18 Kijowski DJ. Responsible conduct of research with computational models. MS Thesis, 2010.

- 19 Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices – overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. *Medical Decision Making*. 2012;**32**(5):667–77.
- 20 Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. *Journal of Clinical Epidemiology*. 1992;**45**:197–203.
- 21 Fishman PA, Goodman MJ, Hornbrook MC, Meenan RT, Bachman DJ, O’Keefe Rosetti MC. Risk adjustment using automated ambulatory pharmacy data: the RxRisk model. *Medical Care*. 2003;**41**:84–99.
- 22 Andre T, Sargent D, Tabernero J, O’Connell M, Buyse M, Sobrero A, et al. Current issues in adjuvant treatment of stage II colon cancer. *Annals of Surgical Oncology*. 2006;**13**:887–98.
- 23 Jansman FG, Postma MJ, Brouwers JR. Cost considerations in the treatment of colorectal cancer. *Pharmacoeconomics*. 2007;**25**:537–62.
- 24 Rajpal S, Venook AP. Targeted therapy in colorectal cancer. *Clinical Advances in Hematology & Oncology*. 2006;**4**:124–32.
- 25 Tilson L, Sharp L, Usher C, Walsh C, O’Ceilleachair A, Stuart C, et al. Cost of care for colorectal cancer in Ireland: a health care payer perspective. *European Journal of Health Economics*. 2012;**13**:511–24.
- 26 Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. *New England Journal of Medicine*. 2000;**342**:1887–92.
- 27 Concato J. Observational versus experimental studies: what’s the evidence for a hierarchy? *NeuroRx*. 2004;**1**:341–7.
- 28 Avorn J. In defense of pharmacoepidemiology – embracing the yin and yang of drug research. *New England Journal of Medicine*. 2007;**357**:2219–21.
- 29 Schneeweiss S, Avorn J. Postmarketing studies of drug safety. *British Medical Journal*. 2011;**342**:d342.
- 30 Berger ML, Mamdani M, Atkins D, Johnson ML. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report – Part I. *Value in Health*. 2009;**12**:1044–52.
- 31 Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppert T, et al. A new taxonomy for describing and defining adherence to medications. *British Journal of Clinical Pharmacology*. 2012;**73**:691–705.
- 32 DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. *Medical Care*. 2002;**40**:794–811.
- 33 Hughes D, Cowell W, Koncz T, Cramer J. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. *Value in Health*. 2007;**10**:498–509.
- 34 Hughes DA, Tilson L, Drummond M. Estimating drug costs in economic evaluations in Ireland and the UK: an analysis of practice and research recommendations. *Pharmacoeconomics*. 2009;**27**:635–43.
- 35 Hay JW, Smeeding J, Carroll NV, Drummond M, Garrison LP, Mansley EC, et al. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report – Part I. *Value in Health*. 2010;**13**:3–7.
- 36 Health and Social Care Information Centre 2014. Use of NICE Appraised Medicines in the NHS in England – 2012, Experimental Statistics. Table 1. Available from: <http://www.hscic.gov.uk/catalogue/PUB13413/use-nice-app-med-nhs-exp-stat-eng-12-rep.pdf> (last accessed 18 November 2015).
- 37 Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veenstra DL. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. *Health Policy*. 2010;**96**:179–90.
- 38 Walker S, Sculpher M, Claxton K, Palmer S. Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions. *Value in Health*. 2012;**15**:570–9.
- 39 Holloway K, Green T. *Drug and Therapeutics Committees: A Practical Guide*. Geneva, World Health Organization, 2003.
- 40 Mamdani M, McNeely D, Evans G, Hux J, Oh P, Forde N, Conly J. Impact of a fluoroquinolone restriction policy in an elderly population. *American Journal of Medicine*. 2007;**120**:893–900.
- 41 Usher C, Tilson L, Bennett K, Barry M. Cost containment interventions introduced on the community drugs schemes in Ireland-evaluation of expenditure trends using a national prescription claims database. *Clinical Therapy*. 2012;**34**:632–9.